【摘要】：隨著我國醫(yī)藥流通體制改革的不斷深入,我國第三方醫(yī)藥電子商務(wù)在為集中招標(biāo)采購提供服務(wù)的的基礎(chǔ)上迅速的發(fā)展,以低成本、高效率、高透明度的特點(diǎn)給傳統(tǒng)醫(yī)藥流通體制帶來了強(qiáng)力沖擊。但是其發(fā)展與美國相比還有很多的不足。本文旨在通過對美國第三方醫(yī)藥電子服務(wù)在各個(gè)領(lǐng)域的廣度與深度進(jìn)行研究,為我國第三方醫(yī)藥電子商務(wù)未來發(fā)展提供參考 本文采用內(nèi)容分析方法,對1996年到2011年間國內(nèi)外醫(yī)藥電子商務(wù)相關(guān)文獻(xiàn)進(jìn)行分析研究；采用實(shí)地調(diào)研方法,南京海虹醫(yī)藥電子商務(wù)行業(yè)研究中心進(jìn)行實(shí)地調(diào)研并收集大量資料,對我國醫(yī)藥行業(yè)應(yīng)用電子商務(wù)所形成的主要的藥電子商務(wù)的服務(wù)進(jìn)行分析；采用對比研究的方法,對美國同類成熟模式進(jìn)行比較分析。 研究內(nèi)容涉及5個(gè)方面：(1)我國醫(yī)藥流通領(lǐng)域的現(xiàn)狀；(2)政府藥品集中招標(biāo)采購的現(xiàn)狀與問題；(3)積極引入第三方醫(yī)藥電子商務(wù)所取得成效與不足；(4)國外第三方醫(yī)藥電子商務(wù)的現(xiàn)狀；(5)國外第三方醫(yī)藥電子商務(wù)對我國第三方醫(yī)藥電子商務(wù)的啟示 研究表明我國第三方醫(yī)藥電子商務(wù)雖然為制藥企業(yè)、醫(yī)藥流通企業(yè)及醫(yī)院,提供了成交撮合、合同管理、網(wǎng)上交易、第三方結(jié)算、數(shù)據(jù)分析等電子商務(wù)服務(wù)。在此期間積累了近十多年的數(shù)據(jù),掌握了大量的醫(yī)藥行業(yè)數(shù)據(jù),并為行業(yè)主管部門提供電子化的監(jiān)管手段,從一定程度上降低了藥品采購的價(jià)格。但與美國相比,其提供的服務(wù)的深度和廣度均不夠。這也是其發(fā)展至今仍未能真正完全融入醫(yī)藥流通所有環(huán)節(jié)中的原因之一,第三方醫(yī)藥電子商務(wù)在整個(gè)行業(yè)中的地位,目前還比較邊緣化。我國應(yīng)該學(xué)習(xí)美國第三方醫(yī)藥電子商務(wù)PBM的的先進(jìn)經(jīng)驗(yàn),積極發(fā)展我國第三方醫(yī)藥電子商務(wù),使其深入到流通渠道的醫(yī)保社保,商業(yè)保險(xiǎn),生產(chǎn)企業(yè),醫(yī)院等各個(gè)環(huán)節(jié)中,實(shí)現(xiàn)物流,商流,資金流的高速運(yùn)轉(zhuǎn),加速流通體制的改革
[Abstract]:With the deepening of the reform of medicine circulation system in our country, the third party medicine electronic commerce in our country develops rapidly on the basis of providing services for centralized bidding and purchasing, with low cost and high efficiency. The characteristics of high transparency bring a strong impact to the traditional medicine circulation system. But its development still has many shortcomings compared with the United States. The purpose of this paper is to study the breadth and depth of third-party pharmaceutical electronic services in the United States in order to provide a reference for the future development of third-party pharmaceutical electronic commerce in China. From 1996 to 2011, domestic and foreign medical electronic commerce related documents were analyzed and studied. By using the field investigation method, Nanjing Haihong Medical Electronic Commerce Industry Research Center carries on the field investigation and collects the massive data, carries on the analysis to the main medicine electronic commerce service which our country medicine profession uses the electronic commerce; A comparative analysis of similar mature models in the United States was carried out by means of comparative study. The research involves five aspects: (1) the current situation in the field of pharmaceutical circulation in China; (2) the current situation and problems of centralized bidding and procurement of government drugs; (3) the achievements and shortcomings of introducing the third party medicine electronic commerce actively; (4) the current situation of foreign third party medicine electronic commerce; (5) the research on the enlightenment of foreign third party medicine electronic commerce to the third party medicine electronic commerce of our country shows that the third party medicine electronic commerce of our country provides the dealmaking for pharmaceutical enterprises, pharmaceutical circulation enterprises and hospitals. Contract management, online trading, third-party settlement, data analysis and other e-commerce services. During this period, more than ten years of data have been accumulated, a large number of pharmaceutical industry data have been grasped, and electronic means of supervision have been provided for the competent departments of the industry, which has reduced the price of drug procurement to a certain extent. But compared with the United States, it provides not enough depth and breadth of service. This is also one of the reasons that its development has not been fully integrated into all the links in the circulation of medicine, and the status of the third party medicine e-commerce in the whole industry is still relatively marginalized at present. Our country should learn from the advanced experience of PBM in third-party pharmaceutical e-commerce in the United States, and actively develop the third-party pharmaceutical e-commerce in China, so that it can penetrate into various links such as health insurance, commercial insurance, production enterprises, hospitals, and so on, in the circulation channels of health insurance, commercial insurance, production enterprises, hospitals, etc. Realize the high speed operation of logistics, commercial flow and capital flow, accelerate the reform of circulation system
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2011
【分類號】：R95

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李蓓新;B2B是醫(yī)藥電子商務(wù)的主流[J];電子商務(wù);2001年03期

2 耿凡;卞鷹;;醫(yī)藥電子商務(wù)B2B模式的發(fā)展及我國醫(yī)藥產(chǎn)業(yè)電子商務(wù)發(fā)展的策略研究[J];商場現(xiàn)代化;2006年35期

3 王志強(qiáng);胡大琴;金新政;;我國B2B醫(yī)藥電子商務(wù)發(fā)展戰(zhàn)略研究[J];商場現(xiàn)代化;2008年34期

4 李云;孫利偉;;第三方醫(yī)藥電子商務(wù)模式的發(fā)展[J];山西醫(yī)藥雜志(下半月刊);2009年06期

5 耿凡;卞鷹;;我國醫(yī)藥第三方電子交易平臺(tái)的SWOT分析[J];商業(yè)時(shí)代;2007年19期

6 胡海寧,雷海潮;美國藥品利益管理公司的服務(wù)內(nèi)容[J];衛(wèi)生經(jīng)濟(jì)研究;2002年03期

7 呂旭飛;;“欣弗”事件暴露的問題及其對策[J];衛(wèi)生經(jīng)濟(jì)研究;2007年03期

8 牛麗萍;苘英麗;;基于價(jià)值鏈理論的電子商務(wù)模式分析[J];現(xiàn)代企業(yè)教育;2009年05期

9 陳玉文;李野;范s，

本文編號：2399009